TORONTO, Sept. 12 – Transition Therapeutics Inc.
(“Transition” or the “Company”) (NASDAQ:TTHI, TSX:TTH) today announced that
the first patient has been dosed in a Phase 2 clinical study of gastrin
analogue, TT-223, in patients with type 2 diabetes. The study is a
randomized, double-blind, placebo-controlled, dose-ranging study to
evaluate the safety, tolerability and efficacy of daily TT-223 treatments
for 12 weeks with a 6-month follow-up. Approximately 80 patients with type
2 diabetes are expected to be enrolled in the study and will receive a
daily treatment of TT-223 in addition to their current regimen of oral
glucose lowering agents (metformin and/or thiazolidinediones).
For information on enrollment, patients or caregivers can visit the
Company’s website http://www.transitiontherapeutics.com or send inquiries directly
by email to clinicaltrials@transitiontherapeutics.com.
Transition and Eli Lilly and Company (NYSE:LLY) have entered into a
licensing and collaboration agreement granting Lilly exclusive worldwide
rights to develop and commercialize gastrin based therapies, including the
lead compound TT-223. Gastrin based therapies are an emerging class of
potential disease-modifying therapies for patients with diabetes, and have
been shown to provide sustained improvement in glycemic control in
preclinical models and early clinical studies. Sustained improvement in
glycemic control is a key goal for patients with diabetes in order to
alleviate the symptoms of hyperglycemia and to prevent diabetic
complications, and improving their overall quality of life.
About Transition
—————-
Transition is a biopharmaceutical company, developing novel
therapeutics for disease indications with large markets. Transition’s lead
products include ELND005 (AZD-103) for the treatment of Alzheimer’s disease
and TT-223 for the treatment of diabetes. Transition has an emerging
pipeline of preclinical drug candidates acquired externally and developed
internally using its proprietary drug discovery engine. Transition’s shares
are listed on the NASDAQ under the symbol “TTHI” and the Toronto Stock
Exchange under the symbol “TTH”. For additional information about the
Company, please visit http://www.transitiontherapeutics.com.
Notice to Readers: Information contained in our press releases should
be considered accurate only as of the date of the release and may be
superseded by more recent information we have disclosed in later press
releases, filings with the OSC, SEC or otherwise. Except for historical
information, this press release may contain forward-looking statements,
relating to expectations, plans or prospects for Transition, including
conducting clinical trials. These statements are based upon the current
expectations and beliefs of Transition’s management and are subject to
certain risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. These
risks and uncertainties include factors beyond Transition’s control and the
risk factors and other cautionary statements discussed in Transition’s
quarterly and annual filings with the Canadian commissions.
SOURCE Transition Therapeutics Inc.